



Jubilant Life Sciences Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

<http://www.jubl.com>

Press Release

Noida, Saturday, August 8, 2020

- **Shyam S. Bhartia calls on the Hon'ble Chief Minister of Uttar Pradesh**
- **Remdesivir ('JUBI-R') presented to Shri Yogi Adityanath**
- **Jubilant donates 1000 vials of Remdesivir to UP Government**

The **Hon'ble Chief Minister of Uttar Pradesh Shri Yogi Adityanath** today, received Remdesivir ('JUBI-R') from **Mr. Shyam S. Bhartia, Chairman, Jubilant Life Sciences Limited**. This COVID-19 medicine was researched at Jubilant's Noida R&D facilities.

On the occasion, Shri Yogi Adityanath said, "Remdesivir is an effective medicine in the treatment of severe COVID-19 cases. In this critical situation, I am pleased that this medicine was made available by Jubilant in the quick time of two and a half months." The Chief Minister noted that Jubilant has a large presence in UP and he also invited Jubilant to make further investments and look at the opportunities in the pharmaceutical sector.

In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc., that granted it the right to register, manufacture and sell Gilead's investigational drug remdesivir in 127 countries including India. Jubilant, recently launched Remdesivir injection under the brand name 'JUBI-R' in the Indian market. The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the Company's distribution network. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory confirmed COVID-19.

"It gives us immense pleasure and satisfaction to present 'JUBI-R' the life-saving medicine to Hon'ble Chief Minister of Uttar Pradesh Shri Yogi Adityanath. We are delighted to support the Uttar Pradesh Government in its fight against COVID-19 by donating 1000 vials of JUBI-R (Remdesivir) through our CSR arm, the Jubilant Bhartia Foundation. We are thankful to the Uttar Pradesh Government for its support in producing this critical drug in a short span of time. Jubilant remains committed to the cause of providing leading healthcare solutions addressing the needs of the patients." **stated Mr. Shyam S. Bhartia, Chairman, Jubilant Life Sciences Limited.**



About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharmaceuticals business, through Jubilant Pharma Limited, Singapore (JPL), is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics. DDS provides innovation and collaborative research through two world class research centers in Bengaluru and Noida in India and Jubilant Therapeutics is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 8,000 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info, please visit www.jubl.com.

For more information, please contact:

For Investors

Hemant Bakhru
Jubilant Life Sciences Limited
E-mail: hemant.bakhru@jubl.com

Siddharth Rangnekar
CDR India
E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya
Jubilant Life Sciences Limited
E-mail: sudhakar.safaya@jubl.com

Desiree Crasto
Madison Public Relations
E-mail: desiree.crasto@madisonpr.in
Phone number: +91 9819541498



Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.